U.S. Leaders Sign Letter to President Biden to Lead G-7 Effort to Vaccinate Majority of the World's Population by Year-End
A group of 34 leaders from business, government, medicine and academia today published an open letter in the Wall Street Journal, urging U.S. President Joseph R. Biden to lead a G-7 effort to extend Covid-19 vaccinations to the world's most afflicted regions.
"Millions of people in Latin America, Africa and Southeast Asia continue to have little or no access to vaccines and remain desperate as the delta variant becomes increasingly rampant worldwide," the letter says. "Helping to vaccinate populations in other countries is an investment in our own safety as well as global stability."
The letter notes that at the G-7 meeting in June, member countries made commitments to eradicate the disease and revitalize the world's democracies. A coordinated global plan is the best way to advance both those goals.
The non-partisan group of leaders was organized by Maurice R. Greenberg, Chairman and CEO of C. V. Starr & Co., Inc. The full text of the letter is attached.
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...
Amgen and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood...
Emmy-winning actor and St. Louis native Jon Hamm took the stage Saturday, May 18, to offer words of wisdom to the newest graduates of Saint Louis University (SLU) during the University's spring commencement in St. Louis. ...
Nearly 900 undergraduates of the Class of 2024 celebrated their send-off from Bentley University in a very different way than their 2020 arrival amid the COVID-19 pandemic. The 105th undergraduate commencement ceremony was marked by maskless smiles,...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...
